Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease (CVD) morbidity and mortality worldwide. Renin-angiotensin system (RAS) blockers have been indispensable in diminishing the macrovascular and microvascular complications of diabetes. In addition, cumulative evidence from retrospective studies pointed toward a beneficial effect of RAS agents in preventing the development and progression of T2DM. This disease-modifying potential of RAS blockers has been substantiated by recent prospective trials. Contemporary concepts regarding the natural history of T2DM and the pathophysiologic processes involved have increased our understanding of the mechanisms underlying the therapeutic potential of these agents in diabetes management. In addition to their established roles in the primary prevention of CVD in patients with diabetes, RAS blockers might be considered a suitable therapeutic choice for preventing the development of frank diabetes in high-risk patients.
International Diabetes Federation: The Diabetes Atlas, 4th Edition. Brussels: International Diabetes Federation; 2009.
Ramlo-Halsted BA, Edelman SV: The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clin Diabetes 2000, 18:80–85.
Twigg SM, Kamp MC, Davis TM, et al.: Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007, 186:461–465. PubMed
Fowler MJ: Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008, 26:77–82. CrossRef
American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010, 121:e46–e215. CrossRef
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.
Barzilay JI, Davis BR, Cutler JA, et al.: Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006, 166:2191–2201. CrossRefPubMed
Figueroa CD, Dietze G, Muller-Esterl W: Immunolocalization of bradykinin B2 receptors on skeletal muscle cells. Diabetes 1996, 45:S24–S28. PubMed
Rett K, Wicklmayr M, Dietze GJ, Haring HU: Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 1996, 45:S66–S69. PubMed
Roberts CK, Barnard RJ, Scheck SH, Balon TW: Exercise-stimulated glucose transport in skeletal muscle is nitric oxide dependent. Am J Physiol Endocrinol Metab 1997, 273:E220–E225.
Rueckschloss U, Quinn MT, Holtz J, Morawietz H: Dose-dependent regulation of NADPH oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002, 22:1845–1851. CrossRefPubMed
Dragovic T, Minshall R, Jackman HL, et al.: Kininase II-type enzymes. Their putative role in muscle energy metabolism. Diabetes 1996, 45:S34–S37. PubMed
Rong X, Li Y, Ebihara K, et al.: Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia 2010 Apr 15 [Epub ahead of print].
• NAVIGATOR Study Group, McMurray JJ, Holman RR, et al.: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1477–1490. The NAVIGATOR trial was a large, prospective, randomized study that found that in high-risk patients with prediabetes, treatment with ARB was associated with significant reduction in the incidence of new-onset diabetes. CrossRefPubMed
American Diabetes Association: Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl 1):S12–S54. CrossRef
- The Role of Renin-Angiotensin Agents in Altering the Natural History of Type 2 Diabetes Mellitus
Joel A. Lardizabal
Prakash C. Deedwania
- Current Science Inc.
Neu im Fachgebiet Kardiologie
Mail Icon II